Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $644.37 million. The enterprise value is $341.13 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 50.36 million shares outstanding. The number of shares has increased by 0.54% in one year.
| Current Share Class | 50.40M |
| Shares Outstanding | 50.36M |
| Shares Change (YoY) | +0.54% |
| Shares Change (QoQ) | +2.05% |
| Owned by Insiders (%) | 7.62% |
| Owned by Institutions (%) | 42.90% |
| Float | 21.68M |
Valuation Ratios
The trailing PE ratio is 48.54 and the forward PE ratio is 21.23.
| PE Ratio | 48.54 |
| Forward PE | 21.23 |
| PS Ratio | 7.97 |
| Forward PS | 6.38 |
| PB Ratio | 2.78 |
| P/TBV Ratio | 2.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 26.18 |
| EV / Sales | 4.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.70, with a Debt / Equity ratio of 0.16.
| Current Ratio | 6.70 |
| Quick Ratio | 6.60 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.82 |
Financial Efficiency
Return on equity (ROE) is 6.23% and return on invested capital (ROIC) is -8.90%.
| Return on Equity (ROE) | 6.23% |
| Return on Assets (ROA) | -5.65% |
| Return on Invested Capital (ROIC) | -8.90% |
| Return on Capital Employed (ROCE) | -9.59% |
| Revenue Per Employee | $795,928 |
| Profits Per Employee | $134,340 |
| Employee Count | 97 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $27.05 million in taxes.
| Income Tax | 27.05M |
| Effective Tax Rate | 67.49% |
Stock Price Statistics
The stock price has increased by +51.09% in the last 52 weeks. The beta is 0.01, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | +51.09% |
| 50-Day Moving Average | 11.15 |
| 200-Day Moving Average | 9.78 |
| Relative Strength Index (RSI) | 73.09 |
| Average Volume (20 Days) | 235,964 |
Short Selling Information
The latest short interest is 4.12 million, so 8.19% of the outstanding shares have been sold short.
| Short Interest | 4.12M |
| Short Previous Month | 3.95M |
| Short % of Shares Out | 8.19% |
| Short % of Float | 19.02% |
| Short Ratio (days to cover) | 25.56 |
Income Statement
In the last 12 months, TBPH had revenue of $77.21 million and earned $13.03 million in profits. Earnings per share was $0.26.
| Revenue | 77.21M |
| Gross Profit | 36.54M |
| Operating Income | -35.63M |
| Pretax Income | -38.22M |
| Net Income | 13.03M |
| EBITDA | -34.31M |
| EBIT | -35.63M |
| Earnings Per Share (EPS) | $0.26 |
Full Income StatementBalance Sheet
The company has $338.80 million in cash and $35.56 million in debt, giving a net cash position of $303.24 million or $6.02 per share.
| Cash & Cash Equivalents | 338.80M |
| Total Debt | 35.56M |
| Net Cash | 303.24M |
| Net Cash Per Share | $6.02 |
| Equity (Book Value) | 224.85M |
| Book Value Per Share | 4.46 |
| Working Capital | 311.66M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 47.33%, with operating and profit margins of -46.16% and 16.88%.
| Gross Margin | 47.33% |
| Operating Margin | -46.16% |
| Pretax Margin | 51.91% |
| Profit Margin | 16.88% |
| EBITDA Margin | -44.44% |
| EBIT Margin | -46.16% |
| FCF Margin | n/a |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.54% |
| Shareholder Yield | -0.54% |
| Earnings Yield | 2.02% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TBPH is $21.33, which is 66.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.33 |
| Price Target Difference | 66.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 27.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |